Directors Casdin and Meister's Funds Acquire Another $21.4M in GeneDx Shares
WGS sits 46% above its 52-week low of $32.21.
Summary
Funds associated with directors Eli Casdin and Keith Meister continued to accumulate GeneDx Holdings Corp. stock, purchasing an additional $21.4 million in open market transactions. This follows recent large insider buys and occurs after the company's Q1 earnings miss and reduced guidance.
Key Events · Ownership and Investor Activity · WGS
-
Significant Insider Accumulation
Funds managed by directors Eli Casdin and Keith Meister acquired 500,000 shares of GeneDx Holdings Corp. Class A Common Stock through open market purchases.
-
Substantial Investment
The total value of these recent purchases, made between May 18-20, 2026, amounts to approximately $21.45 million.
-
Post-Earnings Conviction
These purchases follow the company's recent Q1 earnings report (May 4, 2026) which included a significant net loss and reduced full-year guidance, suggesting strong insider confidence despite recent challenges.
-
Increased Beneficial Ownership
Eli Casdin's beneficial ownership increased to 13.7% and Keith Meister's to 17.9% of the outstanding shares.
Analysis · WGS · Industrial Applications And Services
This Schedule 13D/A filing reveals a continuation of significant insider buying by entities associated with directors Eli Casdin and Keith Meister. The acquisition of an additional $21.45 million in shares, representing over 1.5% of the company's market capitalization, demonstrates strong conviction. This is particularly notable as these purchases occurred in the days following the company's Q1 earnings report, which included a larger-than-expected net loss and a reduction in full-year revenue guidance. The sustained accumulation by these key insiders, despite recent negative news, suggests a belief in the company's long-term prospects and could be interpreted as a vote of confidence.
At the time of this filing, WGS was trading at $47.02 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $32.21 to $170.87. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.